BioSpace News Archive

CentralReach strengthens its position in the Applied Behavior Analysis space with the appointment of Cheryl Michael to Chief Product Officer.

Walgreens Flu Index for week ending January 19, 2019

Novel Packaging and Expression Plasmids Promise to Reduce Gene Therapy Manufacturing Costs and Delivery Times

- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the U.S. Food and Drug Administration (FDA) has completed its review of the Company’s Investigational New Drug (IND) application for AMT-130, and the IND is now effective allowing uniQure to begin its planned Phase I/II study.